LNP-1265
- Generic Name
- LNP-1265
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 130
- Registration Number
- NCT06379789
- Locations
- 🇺🇸
Yale HTC, New Haven, Connecticut, United States
🇺🇸Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
🇬🇧Addenbrooke's Hospital, Cambridge University Hospitals NHS FT, Cambridge, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath